Trial Profile
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders: a Single-Site Pilot Study
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Genetic skin diseases; Pruritus
- Focus Therapeutic Use
- 01 Oct 2023 Planned End Date changed from 1 May 2026 to 1 Jun 2026.
- 01 Oct 2023 Planned primary completion date changed from 31 Mar 2025 to 30 Jun 2025.
- 01 Oct 2023 Status changed from not yet recruiting to recruiting.